Literature DB >> 1868460

Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.

F F Kadlubar1, K L Dooley, C H Teitel, D W Roberts, R W Benson, M A Butler, J R Bailey, J F Young, P W Skipper, S R Tannenbaum.   

Abstract

The human urinary bladder carcinogen, 4-aminobiphenyl (ABP), is known to undergo hepatic metabolism to an N-hydroxy arylamine and its corresponding N-glucuronide. It has been proposed that these metabolites are both transported through the blood via renal filtration to the urinary bladder lumen where acidic pH can facilitate the hydrolysis of the N-glucuronide and enhance the conversion of N-hydroxy-4-aminobiphenyl (N-OH-ABP) to a reactive electrophile that will form covalent adducts with urothelial DNA. Blood ABP-hemoglobin adducts, which have been used to monitor human exposure to ABP, are believed to be formed by reactions within the erythrocyte involving N-OH-ABP that has entered the circulation from the liver or from reabsorption across the urothelium. To test these hypotheses directly, experimental data were obtained from female beagles given [3H]ABP (p.o., i.v., or intraurethrally). [3H]N-OH-ABP (i.v. or intraurethrally), or [3H]N-OH-ABP N-glucuronide (i.v.). Analyses included determinations of total ABP in whole blood and plasma, ABP-hemoglobin adducts in blood erythrocytes, ABP and N-OH-ABP levels (free and N-glucuronide) in urine, urine pH, frequency of urination (controlled by urethral catheter), rates of reabsorption of ABP and N-OH-ABP across the urothelium, and apparent volumes of distribution in the blood/tissue compartment. The major ABP-DNA adduct, N-(guan-8-yl)-4-aminobiphenyl, was also measured in urothelial and liver DNA using a sensitive immunochemical method. An analog/digital hybrid computer was then utilized to construct a multicompartmental pharmacokinetic model for ABP and its metabolites that separates: (a) absorption; (b) hepatic metabolism and distribution in blood and tissues; (c) ABP-hemoglobin adduct formation; (d) hydrolysis and reabsorption in the urinary bladder lumen; and (e) excretion. Using this model, cumulative exposure of the urothelium to free N-OH-ABP was simulated from the experimental data and used to predict ABP-DNA adduct formation in the urothelium. The results indicated that exposure to N-OH-ABP and subsequent ABP-DNA adduct formation are directly dependent on voiding frequency and to a lesser extent on urine pH. This was primarily due to the finding that, after p.o. dosing of ABP to dogs, the major portion of the total N-OH-ABP entering the bladder lumen was free N-OH-ABP (0.7% of the dose), with much lower amounts as the acid-labile N-glucuronide (0.3% of the dose).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868460

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Measurement of urine pH for epidemiological studies on bladder cancer.

Authors:  Juan Alguacil; Ruth M Pfeiffer; Lee E Moore; Manuel Rivas Del Fresno; Rafael Medina-Lopez; Manolis Kogevinas; Roel Vermeulen; Mustafa Dosemeci; Debra T Silverman; Nathaniel Rothman; Montserrat García-Closas
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

2.  European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

Authors:  Thorunn Rafnar; Sita H Vermeulen; Patrick Sulem; Gudmar Thorleifsson; Katja K Aben; J Alfred Witjes; Anne J Grotenhuis; Gerald W Verhaegh; Christina A Hulsbergen-van de Kaa; Soren Besenbacher; Daniel Gudbjartsson; Simon N Stacey; Julius Gudmundsson; Hrefna Johannsdottir; Hjordis Bjarnason; Carlo Zanon; Hafdis Helgadottir; Jon Gunnlaugur Jonasson; Laufey Tryggvadottir; Eirikur Jonsson; Gudmundur Geirsson; Sigfus Nikulasson; Vigdis Petursdottir; D Timothy Bishop; Sei Chung-Sak; Ananya Choudhury; Faye Elliott; Jennifer H Barrett; Margaret A Knowles; Petra J de Verdier; Charlotta Ryk; Annika Lindblom; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Paolo Vineis; Silvia Polidoro; Simonetta Guarrera; Carlotta Sacerdote; Angeles Panadero; José I Sanz-Velez; Manuel Sanchez; Gabriel Valdivia; Maria D Garcia-Prats; Jan G Hengstler; Silvia Selinski; Holger Gerullis; Daniel Ovsiannikov; Abdolaziz Khezri; Alireza Aminsharifi; Mahyar Malekzadeh; Leonard H van den Berg; Roel A Ophoff; Jan H Veldink; Maurice P Zeegers; Eliane Kellen; Jacopo Fostinelli; Daniele Andreoli; Cecilia Arici; Stefano Porru; Frank Buntinx; Abbas Ghaderi; Klaus Golka; José I Mayordomo; Giuseppe Matullo; Rajiv Kumar; Gunnar Steineck; Anne E Kiltie; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson; Lambertus A Kiemeney
Journal:  Hum Mol Genet       Date:  2011-07-12       Impact factor: 6.150

Review 3.  Effects of bladder resorption on pharmacokinetic data analysis.

Authors:  J T Dalton; M G Weintjes; J L Au
Journal:  J Pharmacokinet Biopharm       Date:  1994-06

4.  Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity.

Authors:  Soo-Yeon Kim; Whi-An Kwon; Seung-Pil Shin; Ho Kyung Seo; Soo-Jeong Lim; Yuh-Seog Jung; Hyo-Kyung Han; Kyung-Chae Jeong; Sang-Jin Lee
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

5.  CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer.

Authors:  Sofia Pavanello; Giuseppe Mastrangelo; Donatella Placidi; Marcello Campagna; Alessandra Pulliero; Angela Carta; Cecilia Arici; Stefano Porru
Journal:  Eur J Epidemiol       Date:  2010-06-18       Impact factor: 8.082

6.  Oncological safety and quality of life in men undergoing simultaneous transurethral resection of bladder tumor and prostate: results from a randomized controlled trial.

Authors:  Marco Dellabella; Alessandro Branchi; Luca Gasparri; Redi Claudini; Daniele Castellani
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

7.  The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms.

Authors:  Zhaoyi Li; Ruipeng Hou; Jian Li
Journal:  Int Urol Nephrol       Date:  2013-10-05       Impact factor: 2.370

8.  Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

Authors:  Jong-Wei Hsu; Iawen Hsu; Defeng Xu; Hiroshi Miyamoto; Liang Liang; Xue-Ru Wu; Chih-Rong Shyr; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

9.  Does increased urination frequency protect against bladder cancer?

Authors:  Debra T Silverman; Juan Alguacil; Nathaniel Rothman; Francisco X Real; Montserrat Garcia-Closas; Kenneth P Cantor; Nuria Malats; Adonina Tardon; Consol Serra; Reina Garcia-Closas; Alfredo Carrato; Josep Lloreta; Claudine Samanic; Mustafa Dosemeci; Manolis Kogevinas
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

10.  Effects of lead on 4-aminobiphenyl pharmacokinetics in liver, kidney, spleen, testes, heart, lung and hemoglobin adduct for rat model.

Authors:  Hui-Ming Chen; Tao Qin; Li-Xin Zhao; Xiao-Bai Xu
Journal:  Ecotoxicology       Date:  2002-08       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.